3/25
04:30 pm
nrix
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
Low
Report
Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting
3/19
05:41 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) was upgraded by analysts at Leerink Partnrs to a "hold" rating.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) was upgraded by analysts at Leerink Partnrs to a "hold" rating.
3/17
08:11 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Leerink Partners. They set a "market perform" rating and a $16.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) is now covered by analysts at Leerink Partners. They set a "market perform" rating and a $16.00 price target on the stock.
3/17
07:07 am
nrix
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia [Yahoo! Finance]
Medium
Report
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia [Yahoo! Finance]
3/17
07:00 am
nrix
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Medium
Report
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
3/14
04:00 pm
nrix
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3/13
04:00 pm
nrix
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
Medium
Report
Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors
3/4
08:05 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences [Yahoo! Finance]
3/4
07:00 am
nrix
Nurix Therapeutics to Participate in Upcoming Investor Conferences
Medium
Report
Nurix Therapeutics to Participate in Upcoming Investor Conferences
2/14
07:08 pm
nrix
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/14
04:01 pm
nrix
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/4
07:00 am
nrix
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Low
Report
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
2/3
08:02 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Morgan Stanley from $16.00 to $17.00. They now have an "equal weight" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Morgan Stanley from $16.00 to $17.00. They now have an "equal weight" rating on the stock.
1/29
12:49 pm
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Royal Bank of Canada from $26.00 to $27.00. They now have an "outperform" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Royal Bank of Canada from $26.00 to $27.00. They now have an "outperform" rating on the stock.
1/29
09:10 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $30.00. They now have an "overweight" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at JPMorgan Chase & Co. from $31.00 to $30.00. They now have an "overweight" rating on the stock.
1/29
08:18 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $35.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at HC Wainwright from $35.00 to $36.00. They now have a "buy" rating on the stock.
1/29
08:18 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Needham & Company LLC from $29.00 to $28.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target lowered by analysts at Needham & Company LLC from $29.00 to $28.00. They now have a "buy" rating on the stock.
1/29
08:18 am
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Stifel Nicolaus from $34.00 to $36.00. They now have a "buy" rating on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its price target raised by analysts at Stifel Nicolaus from $34.00 to $36.00. They now have a "buy" rating on the stock.
1/28
04:00 pm
nrix
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
Low
Report
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update
1/22
07:34 am
nrix
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer [Yahoo! Finance]
Low
Report
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer [Yahoo! Finance]
1/22
07:00 am
nrix
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
Low
Report
Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer
1/21
12:46 pm
nrix
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
Low
Report
Nurix Therapeutics, Inc. (NASDAQ: NRIX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
1/13
07:00 am
nrix
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
Medium
Report
Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases
1/6
07:00 am
nrix
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
1/5
11:47 am
nrix
Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me [Seeking Alpha]
Low
Report
Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me [Seeking Alpha]